Filtered By:
Drug: Captopril

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats
This study determined the structural and functional changes in the middle cerebral arteries (MCA) during the progression of MetS and the effects of chronic pharmacological interventions on mitigating vascular alterations in obese Zucker rats (OZR), a translationally relevant model of MetS. The reactivity and wall mechanics of ex vivo pressurized MCA from lean Zucker rats (LZR) and OZR were determined at 7–8, 12–13, and 16–17 wk of age under control conditions and following chronic treatment with pharmacological agents targeting specific systemic pathologies. With increasing age, control OZR demonstrated r...
Source: AJP: Heart and Circulatory Physiology - December 1, 2015 Category: Cardiology Authors: Brooks, S. D., DeVallance, E., d'Audiffret, A. C., Frisbee, S. J., Tabone, L. E., Shrader, C. D., Frisbee, J. C., Chantler, P. D. Tags: CALL FOR PAPERS Source Type: research

Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis
Abstract: Heart failure is a public health problem and a great economic burden for patients and healthcare systems. Suppression of the renin–angiotensin system (RAS) by angiotensin-converting enzyme (ACE)-inhibitors remains the mainstay of treatment for heart failure. However, the abundance of ACE inhibitors makes it difficult for doctors to choose. We performed this network meta-analysis of ACEIs in patients with heart failure in order to address this area of uncertainty. We searched PubMed, Embase, CENTRAL, and Medline. Any randomized controlled trial evaluating the efficacy and safety of captopril, enalapril, lisin...
Source: Medicine - February 1, 2016 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Captopril does not Potentiate Post-Exercise Hypotension: A Randomized Crossover Study
Int J Sports Med DOI: 10.1055/s-0042-123044To evaluate whether captopril (3×50 mg/day) potentiates post-resistance exercise hypotension (PREH) in hypertensives (HT), 12 HT men received captopril and placebo for 4 weeks each in a double-blinded, randomized-crossover design. On each therapy, subjects underwent 2 sessions: Control (C – rest) and Resistance Exercise (RE – 7 exercises, 3 sets to moderate fatigue, 50% of 1 RM –repetition maximum). Measurements were taken before and after 30–60 min (Post1) and 7 h (Post2), and ambulatory blood pressure (BP) was monitored for 24 h. There were no differences in PRE...
Source: International Journal of Sports Medicine - February 19, 2017 Category: Sports Medicine Authors: Queiroz, Andr éia Cristiane Carrenho Sousa, Julio Cesar Silva Silva, Natan Daniel Tobaldini, Eleonora Ortega, Katia Coelho de Oliveira, Edilamar Menezes Brum, Patricia Chakur Montano, Nicola Mion, Decio Tinucci, Ta ís de Moraes Forjaz, Claudia Lucia Tags: Physiology & Biochemistry Source Type: research

Novel phthalamide derivatives as antihypertensive agents: rapid and clean synthesis, in silico and in vivo evaluation
AbstractHypertension is a prevalent progressive disorder and a key risk factor for cardiovascular disease, stroke, and kidney disease. Angiotensin-I-converting enzyme (ACE) inhibitors are the first-line drugs for treating hypertension, but they have many side effects. ACE is a zinc dipeptidyl carboxypeptidase that cleaves the decapeptide angiotensin-I to form the vasopressor angiotensin-II. Since the latter molecule is the main bioactive product of the renin –angiotensin system, its inhibition is a key strategy for hypertension therapy. The aim of this study was to conduct an in silico evaluation of a series of new phtha...
Source: Medicinal Chemistry Research - March 17, 2019 Category: Chemistry Source Type: research

YiQiFuMai Powder Injection Attenuates Coronary Artery Ligation-Induced Heart Failure Through Improving Mitochondrial Function via Regulating ROS Generation and CaMKII Signaling Pathways
This study was carried out in accordance with the recommendations of “Guide for the Care and Use of Laboratory Animals, National Institutes of Health.” The protocol was approved by the “China Pharmaceutical University.” Surgical Preparation The mice were anesthetized with chloral hydrate (4% chloral hydrate, ip). The HF model was induced by CAL as previously reported (Gao et al., 2010). Successful ligation of the coronary artery was confirmed by the occurrence of ST-segment elevation in electrocardiogram. Sham operated mice were performed the same process except left CAL. After ligation, the h...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

Testing the Translational Power of the Zebrafish: An Interspecies Analysis of Responses to Cardiovascular Drugs
The zebrafish is rapidly emerging as a promising alternative in vivo model for the detection of drug-induced cardiovascular effects. Despite its increasing popularity, the ability of this model to inform the drug development process is often limited by the uncertainties around the quantitative relevance of zebrafish responses compared with non-clinical mammalian species and ultimately humans. Here we provide a comparative quantitative analysis of the in vivo cardiovascular responses of zebrafish, rat, dog, and human to three model compounds (propranolol, losartan, and captopril), which act as modulators of two key systems ...
Source: Frontiers in Pharmacology - August 15, 2019 Category: Drugs & Pharmacology Source Type: research

Snake venom three-finger toxins and their potential in drug development targeting cardiovascular diseases.
Abstract Cardiovascular diseases such as coronary and peripheral artery diseases, venous thrombosis, stroke, hypertension, and heart failure are enormous burden to health and economy globally. Snake venoms have been the sources of discovery of successful therapeutics targeting cardiovascular diseases. For example, the first-in-class angiotensin-converting enzyme inhibitor captopril was designed largely based on bradykinin-potentiating peptides from Bothrops jararaca venom. In the recent years, sensitive and high throughput approaches drive discovery and cataloging of new snake venom toxins. As one of the largest c...
Source: Biochemical Pharmacology - June 20, 2020 Category: Drugs & Pharmacology Authors: Manjunatha Kini R, Yeow Koh C Tags: Biochem Pharmacol Source Type: research

Phthalamide derivatives as ACE/AChE/BuChE inhibitors against cardiac hypertrophy: an in silico, in vitro, and in vivo modeling approach
This study aimed to synthesize three phthalamide derivatives (M-01, M-02, and M-03) and evaluate them as three-target (ACE/AChE/BuChE) inhibitors with the possible dual effect of reducing hypertension and r everting cardiac hypertrophy. After in silico and in vitro experiments, one compound was tested in vivo on rats. All three phthalamides were synthesized in good yields, showing good competitive inhibition of the three-target enzymes in silico and in vitro. M-01 (10 mg/kg) significantly reversed ca rdiomyocite hypertrophy (by 87.3%;p <  0.001) in the heart of spontaneous hypertensive rat (SHR) model. It was at l...
Source: Medicinal Chemistry Research - February 3, 2021 Category: Chemistry Source Type: research

Therapeutic effect of captopril combined with phosphocreatine sodium on viral myocarditis
CONCLUSION: Captopril combined with phosphocreatine sodium can reduce the inflammatory response in patients with infectious myocarditis, improve cardiac function, and improve the therapeutic efficacy.PMID:36628215 | PMC:PMC9827287
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Yongjin Wang Wanlin Chen Mingliang Li Xuemei Chen Source Type: research